<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300768</url>
  </required_header>
  <id_info>
    <org_study_id>OCRC-33 - 980819(B)</org_study_id>
    <nct_id>NCT00300768</nct_id>
  </id_info>
  <brief_title>Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection</brief_title>
  <official_title>A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines Development Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines Development Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and tolerability of moxidectin
      in subjects infected with O. volvulus with special emphasis on Mazzotti reactions to
      determine whether it is safe enough to expose a number of subjects sufficient for obtaining
      statistically significant data on the safety and efficacy of moxidectin relative to
      ivermectin.

      Secondary objects are to determine the pharmacokinetics of moxidectin, to obtain initial
      indication of the efficacy in terms of long term effect on skin microfilaria levels and an
      indication of the effect on the macrofilaria that may underlie the effect on skin
      microfilaria levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinical adverse events and clinically significant laboratory test results</measure>
    <time_frame>Duration of follow up (18 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin mf counts at day 8 and months 1, 2, 3, 6, 12 and 18</measure>
    <time_frame>day 8 and months 1, 2, 3, 6, 12, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodulectomy at 18 months</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) at days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12</measure>
    <time_frame>days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Onchocerciasis</condition>
  <arm_group>
    <arm_group_label>2 mg moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg moxidectin (Dose-escalation 1st step)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin 150 mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator arm (ivermectin 150 mcg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg moxidectin (dose escalation second step)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg moxidectin (dose escalation third step)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg moxidectin</intervention_name>
    <description>Single-dose, tablet encapsulated for blinding</description>
    <arm_group_label>2 mg moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin 150 mcg/kg</intervention_name>
    <description>Single-dose, tablets encapsulated for blinding</description>
    <arm_group_label>Ivermectin 150 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg moxidectin</intervention_name>
    <description>Single dose, tablets encapsulated for blinding</description>
    <arm_group_label>4 mg moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8 mg moxidectin</intervention_name>
    <description>single dose, tablets encapsulated for blinding</description>
    <arm_group_label>8 mg moxidectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written, signed (or thumb-printed), and dated informed consent

          2. Aged 18 to 60 years, inclusive

          3. Body weight ≥ 40 kg for women and ≥ 45 kg for men

          4. Nonpregnant, nonbreastfeeding women. Women of child bearing potential must agree to
             use birth control during the first 150 days after treatment.

          5. Healthy, as determined by a physician on the basis of a physical examination, ECG, and
             a thorough review of the medical history and clinical laboratory results

          6. Adequate hematologic, renal, and hepatic function

          7. Skin microfilarial density within the required range for the cohort

        Exclusion Criteria:

          1. Participation in any studies other than purely observational ones, within 4 weeks
             before test article administration.

          2. Any vaccination within 4 weeks before test article administration

          3. Acute infection requiring therapy within the last 10 days before test article
             administration

          4. Administration of any medication (with the exception of medication required to treat
             any reactions during the screening fluorescein angiography (chlorpheniramine) or
             paracetamol) or herbal preparation within 10 days prior to test article administration
             or any condition currently requiring regular medication

          5. Clinically significant ECG abnormalities or history of cardiac abnormality

          6. Past or current history of neurological or neuropsychiatric disease or epilepsy

          7. Subjects with orthostatic hypotension at the screening evaluation

          8. History of drug or alcohol abuse or regular use of ≥ 3 cigarettes per day

          9. Use of alcohol or other drugs of abuse within 72 hours before test article
             administration

         10. Any condition, in the investigator's opinion, that places the subject at undue risk

         11. Subjects who have donated blood within 8 weeks before study entry

         12. Subjects with ocular onchocerciasis in cohorts intended to enroll subjects with mild
             infection. Ocular onchocerciasis is defined by the presence of live or dead
             microfilariae, onchocercal punctate opacities, onchocercal lesions of the posterior
             segment or lesions that mimic those seen in onchocerciasis.

         13. Subjects with hyperreactive onchodermatitis

         14. Antifilarial therapy within the previous 5 years

         15. Coincidental infection with Loa Loa

         16. Female subjects of childbearing potential with a contraindication to DMPA if not on
             Norplant

         17. Any other condition which the investigator feels would exclude the subject from the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Opoku, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onchocerciasis Chemotherapy Research Center, Hohoe, Ghana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onchocerciasis Chemotherapy Research Center</name>
      <address>
        <city>Hohoe</city>
        <state>Volta Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072596/pdf/pntd.0002953.pdf</url>
    <description>Awadzi et al 2014</description>
  </link>
  <results_reference>
    <citation>Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2953. doi: 10.1371/journal.pntd.0002953. eCollection 2014 Jun.</citation>
    <PMID>24968000</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>onchocerciasis</keyword>
  <keyword>onchocerca volvulus</keyword>
  <keyword>river blindness</keyword>
  <keyword>ivermectin</keyword>
  <keyword>moxidectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Intestinal Volvulus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Milbemycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

